IBEX 35. DOBLE INVERSO (INDV)

Overview

Indivior PLC operates within the pharmaceutical industry, focusing on the development, manufacture, and sale of buprenorphine-based prescription drugs aimed at treating opioid dependence and related disorders. With a global presence, including significant operations in the United States, the United Kingdom, and other international markets, the company spearheads initiatives to address substance use disorders, serious mental illnesses, and opioid overdose. Established in 2014, Indivior's mission is underscored by its commitment to offer innovative therapeutic solutions, catering to a range of needs within the ambit of opioid use disorder (OUD) and beyond. Headquartered in North Chesterfield, Virginia, Indivior leverages its scientific and operational expertise to advance a pipeline of products and services designed to improve patient outcomes in the areas of substance abuse and mental health.

Products and Services

• SUBLOCADE and SUBUTEX PRO: Buprenorphine extended-release monthly injections, these are core marketed products designed for the sustained management of opioid use disorder. SUBLOCADE is administered as an injectable while SUBUTEX PRO offers a similar long-term relief in managing addiction symptoms.
• SUBOXONE: Available both as a sublingual film and a tablet, SUBOXONE combines buprenorphine and naloxone. This formulation is aimed at reducing opioid cravings and withdrawal symptoms while blocking the high effects of opioid use, thus facilitating recovery and maintenance therapy for those battling opioid addiction.
• SUBUTEX: This is a buprenorphine sublingual tablet formulated to suppress symptoms of opioid withdrawal. By providing a buprenorphine-only product, SUBUTEX is another avenue for patients seeking opioid dependency treatment with a focus on reducing the potential for misuse.
• OPVEE Nasal Spray: A naloxone-based nasal spray, OPVEE is crafted for the rapid reversal of opioid overdose. Its intranasal delivery system is designed for easy administration, making it an essential tool in emergency situations involving opioid intoxication.
• PERSERIS: A long-acting injectable suspension for the treatment of schizophrenia in adults, PERSERIS employs extended-release technology to provide patients with a consistent delivery of medication, aimed at improving the management of schizophrenia symptoms over time.
• Research and Development: Indivior is actively engaged in developing a diverse pipeline of treatments for substance use disorders and mental illnesses. Notably, INDV-2000, a promising orexin-1 receptor antagonist, is under clinical trials for opioid use disorder. Collaboration with ADDEX Therapeutics has resulted in INDV-1000, targeting alcohol use disorder, while partnership with Alar Pharmaceuticals Inc. focuses on INDV-6001, a long-acting injectable for OUD. The company's venture into digital therapeutics is highlighted by its development of CT-102 with Click Therapeutics for OUD treatment. Additionally, INDV-5004, aimed at treating acute cannabinoid overdose, and AEF0117, developed in partnership with Aelis Farma for cannabis use disorder, further exemplify Indivior's commitment to addressing a broad spectrum of substance-related disorders.